Oman vs Serbia: Access to anti-retroviral drugs, male
Oman
65.0%
in 2024
Serbia
65.0%
in 2024
Oman rank
83rd
Serbia rank
83rd
Access to anti-retroviral drugs, male over time
- Oman
- Serbia
How they compare
Oman currently reports 65.0% against 65.0% in Serbia, a difference of 0.0%.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Oman ahead.
Oman ranks 83rd and Serbia ranks 83rd of 141 countries.
Serbia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Oman | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 19.7% | 27.8% | 8.1% | Serbia |
| 2010s | 33.4% | 49.3% | 15.9% | Serbia |
| 2020s | 58.4% | 62.8% | 4.4% | Serbia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Oman or Serbia?
- Oman, at 65.0% against 65.0% in Serbia as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Oman and Serbia?
- 0.0%, with Oman ahead.
- How many years of comparable data are there for Oman and Serbia?
- 25 years are reported by both, from 2000 to 2024.
- How do Oman and Serbia rank globally for access to anti-retroviral drugs, male?
- Oman ranks 83rd and Serbia ranks 83rd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.